

	
Europass Curriculum Vitae	
First name/ Surname	Gemma Caterina Maria / Rossi
	<p>European Commission Expert, N. EX2017D303944</p> <p>H-index : 16</p> <p>Research gate score 29.52</p> <p>ORCID ID: orcid.org/0000-0003-3519-2420</p> <p>Publons (web of science researcher ID): ABI-2573-2020</p>
Work experience	
Dates	<p>Since May 1st, 2001 she worked at the Eye Unit of the Azienda Ospedaliera Bolognini of Seriate, Bg, as ophthalmic medical dirigent and as responsible of the “Glaucoma Centre” of the Unit.</p> <p>Since November 3, 2008, she works at the Eye Clinic Of the University of Pavia, Fondazione Policlinico San Matteo, as ophthalmic medical dirigent. She cooperate at the Glaucoma Center of the Eye Clinic.</p> <p>Since January 2019, she cooperate at the Retina Center of the Eye Clinic at Fondazione. Since January 2020, she cooperate at the Cornea Center of the Eye Clinic at Fondazione.</p>
Occupation or position held	Ophthalmic medical dirigent
Main activities and responsibilities	<p>She follows the activity of the glaucoma out patient’s department of the Eye Clinic of the University of Pavia (glaucoma center, perimetry center, YAG-laser center)</p> <p>She follows the activity of the retina out patient’s department of the Eye Clinic of the University of Pavia (retina center, OCT/FAG center, intravitreal treatments)</p>

	<p>She follows the activity of the Cornea Center of the Eye Clinic of the University of Pavia (OCT, Pentacam, cross-linking treatments)</p> <p>She follows the activity of the in patient's department of the Eye Clinic of the University of Pavia</p> <p>She carries out researches on the evolution of glaucoma availing herself of the standard PC perimetry, (SWAP, FDT, HRT, Gdx) and OCT; and on the topical therapy.</p> <p>She has validated the Italian versions of some questionnaire to evaluate quality of life (in glaucoma, in ocular pathologies, in VDT users)</p> <p>Tutor for students of the Degree Course in Orthoptics and ophthalmologists' assistants.</p> <p>Tutor for students of the V-VI year of the course of Medicine and Surgery of the University of Pavia with production of Experimental Theses.</p> <p>Tutor for V-VI students of the Harvey Medical and Surgery Course (in English) of the University of Pavia with production of Experimental Theses.</p> <p>Tutor for doctors enrolled at the School of Specialization in Ophthalmology at the University of Pavia</p>
Name and address of employer	Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19 27100, Pavia
Type of business or sector	Medical doctor specialized in ophthalmology. Ordine dei Medici Chirurghi e Odontoiatri (OMCeO) di Pavia, N. 9138
Education and training	
Dates	<p>High School Diploma (classic study) at the Istituto di Cultura e Lingue "Marcelline", a school run by the Marcelline religious order, of Milano, Via Quadronno.</p> <p>She enrolled in the <i>Università degli Studi</i> of Pavia, Medicine and Surgery Faculty in the academic year 1989-1990; she graduated on July 20, 1995 with an experimental dissertation in Ophthalmology Clinics, entitled "Genetic, Clinic And Instrumental Research On The Association Between Pigmentous Retinosis And Closed Angle Glaucoma", with Professor Fernando Trimarchi, with full marks ad honors.</p> <p>During her university years she attended: Human and hereditary Pathology Department, Section for General biology and Medical Genetics from September 1990 to June 1991; Biochemical Department – Medicine and Pharmacy Section, from June 1991 to October 21, 1992; General Medical Clinics and Medical Therapy at IRCCS Policlinico S. Matteo Hospital, Pavia; Medical Psychology Chair in the Surgery Department from November 1992 to May 1993.</p> <p>She passed her qualifying examination to practice the medical profession in the 1996 session (April-May) with 108/110 marks.</p> <p>She took part to the examination for enrolling into the School for Ophthalmology Specialization at the Università degli Studi di Pavia in the Academic Year 1996/1997, she graduated on October 19, 2000 with a</p>

	sperimental dissertation entitled “Quality of life in glaucoma patients”, with full marks and honors.				
Title of qualification awarded	Medical doctor, ophthalmologist				
Principal subjects/occupational skills covered	Clinical Ophthalmology. Diagnosis and therapy of glaucoma. Diagnosis and therapy of retinal diseases. Intravitreal treatments for retinal diseases. Diagnosis and therapy of ocular surface diseases. Quality of life in patients with eye diseases. Neuroinflammation of the visual system. Dry eye and videoterminal use				
Name and type of organisation providing education and training	Università degli Studi di Pavia				
Level in national or international classification	NA				
Personal skills and competences					
Mother tongue(s)	Italian				
Other language(s)					
Self-assessment	Understanding		Speaking		Writing
<i>European level (*)</i>	Listening	Reading	Spoken interaction	Spoken production	
Language (English)	C1	C2	C1	C1	C2
Language (French)	B1	C2	B1	B1	B1
	<i>(*) Common European Framework of Reference for Languages</i>				
Social skills and competences	<p>Excellent relationship with patients and colleagues. Excellent coordinating activity in the clinical and research activity of the glaucoma center Excellent coordinating activity as principal investigator in clinical trials.</p> <p>Since 2003 contract professor at the School for Ophthalmology Specialization with the course: “Perimetric defects in neurophthalmology”.; Since 2011 contract professor at the School for Ophthalmology Specialization with the course: “glaucoma therapy and its impact on ocular</p>				

	<p>surface”.</p> <p>She attended more than 200 national and international congresses as a reporter</p> <p>From 2012 to 2014 she was the North Italy Tutor of the educational program for general territory ophthalmologists of the “Progetto Delfini” supported by MSD.</p> <p>Member of the Glaucoma Advisory board for Santen (2015-2017).</p> <p>Member of the Glaucoma Advisory board for Alcon (2015-2018, now Novartis).</p> <p>Member of the Ocular Surface Advisory board for Farmigea (2016).</p> <p>Member of the Cypass Italian Advisory Board (2017, Alcon)</p> <p>Member of the advisory board: glaucoma and neuroprotection (2021-22, Omega pharma)</p> <p>With other Italian Glaucomas' opinion leaders, with the support of Novartis, she has developed a new algorithm for the evaluation of the risk of progression of glaucoma, in the years 2015-2016.</p>
<p>Organisational skills and competences</p>	<p>Scientific secretary for the following courses:</p> <ul style="list-style-type: none"> - Perimetria automatizzata Humphrey – Strategie tradizionali e nuove metodiche a confronto – 28 mag 1999, Clinica Oculistica dell’Università di Pavia - Sclerectomia profonda – 11giu 1999, Clinica Oculistica dell’Università di Pavia - Attualità nella diagnosi e nella terapia del Glaucoma – 2 giu 2000, Clinica Oculistica dell’Università di Pavia - Il glaucoma: riconsideriamolo insieme. Nuove prospettive nella patogenesi e nel trattamento del glaucoma – 30 mag 2003, Clinica Oculistica dell’Università di Pavia - Nuovi fattori di rischio e nuove linee guida per il trattamento del glaucoma, 2 Apr 2004, Biblioteca AO Bolognini di Seriate - Diagnosi clinica e strumentale di glaucoma ad angolo aperto: applicazione dei nuovi orientamenti diagnostici, 28 Mag 2004, Biblioteca AO Bolognini di Seriate - Opzioni terapeutiche per il glaucoma ad angolo aperto, 15 Ott 2004, Biblioteca AO Bolognini di Seriate; - Il glaucoma pseudoesfoliativo, 20 maggio 2005, Biblioteca AO Bolognini di Seriate - La sindrome dell’occhio secco, 6 ottobre 2007, Praga - Le malattie neurodegenerative dell’occhio, 16-17 nov 2007, Costigliole Saluzzo - La sindrome dell’occhio secco nei pazienti in terapia topica cronica, 28 settembre 2008, Riga - Il rischio vascolare nel glaucoma, 8 giugno 2009, Pavia.

- Argomenti di Neuroftalmologia, 21 settembre 2009, Pavia
- La progressione nel glaucoma, 19 ottobre 2009, Pavia
- Progetto glaucoma, 11 settembre 2017, Pavia
- I glaucomi difficili, 28-29 settembre 2018, Pavia

Principal Investigator in Clinical Studies:

Settembre 2004: Studio di fase IV: “Efficacia ipotonizzante e tollerabilità di Travoprost in pazienti con glaucoma primario ad angolo aperto e/o ipertensione oculare, non controllati dal trattamento con beta-bloccanti o intolleranti ad esso”.

Dicembre 2007: Studio multicentrico di fase IV: “Sicurezza ed efficacia della combinazione fissa Timololo 0,5%/Travoprost 0,004% verso l’associazione non fissa Timololo 0,5% e Latanoprost 0,005% in pazienti con glaucoma primario ad angolo aperto e/o ipertono oculare. Studio prospettico a 6 mesi”.

Gennaio 2009: Studio multicentrico di fase III: “Parallel multicenter, double masked, active controlled, four arm, randomized study to evaluate efficacy and safety of Travoprost/Brinzolamide fixed combination PM vs Travoprost/Brinzolamide fixed combination AM vs Travoprost PM and vs Brinzolamide BID in poag or ocular hypertension” Prot C-07-63

Giugno 2009: Use of an electronic monitoring tool to record adherence rates and to evaluate visual field progression.

Gennaio 2010: Treatment of the ocular surface damage following phacoemulsification with new artificial tears. A randomized controlled clinical trial

Febbraio 2010: The Italian version of the Glaucoma Symptom Scale questionnaire: Translation, Validation and Reliability.

Marzo 2010: Pentacam’s sensitivity and specificity in detecting occludable angles.

Ottobre 2010: Effect of preservative free timolol 0,50% and preservative free tafluprost on ocular surface status (signs and symptoms). Multicentric randomized single blind one year study on newly diagnosed patients.

Febbraio 2011: Studio fase III; Safety and IOP-lowering efficacy of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL Eye Drops, Solution in Patients with Open-Angle Glaucoma or Ocular Hypertension. Protocol Number. C-10-040.

Maggio 2011: Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients.

Novembre 2011: Studio fase IV; Multicenter study assessing efficacy and tolerability of Travatan solution without BAK, containing Polyquad Preservative (0,004% travoprost) in patients previously on latanoprost 0,005% or bimatoprost 0,01% ophthalmic solution monotherapy

Sept 2012. IRFMN-OG1 Observational study on quality of life in glaucoma.

June 2013: 006-02 Studio prospettico longitudinale osservazionale per la valutazione dello sviluppo di sofferenza della superficie oculare nel trattamento di pazienti affetti da glaucoma e ipertensione oculare non trattati in precedenza nei confronti di pazienti senza un'elevata pressione intraoculare (Sahara-Italia)

Jan 2014: Systane Balance study M-13027; Clinical Evaluation of an Oil-based Lubricant Eye Drop in Dry Eye Patients With Lipid Deficiency.

February 2015: The medical therapy in naïve or treated glaucoma and hypertensive patients: following glaucoma evolution. A prospective cohort study (Prot OCU-GLC 2014)

4 feb 2015: Effect of Palmitoylethanolamide on inner retinal function in stable glaucoma patients. A prospective, randomized, single blind, crossover clinical trial by pattern electroretinogram. (PEA2015)

February 2015: The Italian version of the Computer-Vision Symptom Scale questionnaire: Translation, Validation and Reliability.(CVSS17)

June 2017: Preservative-free fixed-dose combination of Tafluprost 0.0015%/Timolol0.5% in patients with open-angle glaucoma or ocular hypertension: clinical effectiveness, tolerability and safety in a real world setting (Protocol – 0240-0024) (Phase 3)

september 2017: Effect of the fixed combination Neuprozin® (Citicoline 500 mg plus Homotaurine 50 mg) on pattern electroretinogram (PERG) in patients with primary open angle glaucoma on well controlled intraocular pressure. A multicenter, prospective, randomized, single blind, cross-over study. (Coordinator center) (Phase 2)

	<p>October 2017: Randomized, double blind, controlled trial evaluating the effects of an ophthalmic solution of Coenzyme Q10 and Vitamin E in patients affected by open-angle glaucoma. CoQun Study (Phase 3)</p> <p>November 2017: A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT® (bimatoprost 0.03%/timolol 0.5% Ophthalmic Solution) in subjects with elevated intraocular pressure (MERCURY 3) (PG324-CS303) (phase3)</p> <p>June 2021: A PHASE III, MULTINATIONAL, MULTICENTER, INVESTIGATOR-MASKED, RANDOMISED, ACTIVE- CONTROLLED TRIAL, COMPARING THE EFFICACY AND SAFETY OF DE-130A WITH XALATAN® IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION OVER 3 MONTHS, AND WITH A 12-MONTH FOLLOW-UP WITH OPEN- LABEL DE-130A TREATMENT (EudraCT 2017 004262-95)</p> <p>August 2021: "Effect of oral citicoline on the visual function of glaucoma patients undergoing filtering surgery" - Prot. CHIRCIT</p> <p>Subinvestigator</p> <p>december 2021: <i>A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension</i>” with the Protocol number 1698-301-007. (Bimatoprost SR 1698-301-007 TRITON study)</p>
	<p>Since April 2014, she is responsible, at the Scientific Direction Unit of the Fondazione Policlinico San Matteo of Pavia, of a “Clinical Current Research” entitled “Glaucoma therapy: the efficacy in the respect of the safety”.</p> <p>From January 2016 she has reached, from the Scientific Direction of the Fondazione, a scholarship for an Ophthalmologist Assistant to conduct a study entitled “PERG and confocal microscopy in the follow-up of POAG patients on topical therapies”.</p> <p>Since december 2021 she has been invited to cooperate with the UCL Queen Square Institute of Neurology University College London, UK to investigate the visual system from the eye to the visual cortex in subjects who were infected by SARS-COV-2.</p>
	<p>ICH E6-R2/GCP training : renewed on Oct, 2021</p> <p>IATA certification: renewed on Oct 31, 2016</p>
<p>Technical skills and competences</p>	<p>2003, invited reviewer for “Health and quality of life outcomes”</p>

2009, invited referee for “Expert opinion in pharmacotherapy”

2010: invited reviewer for “ Experimental and clinical pharmacology“;
“Methods and findings in Experimental and Clinical
Pharmacology”;
“Eye”
“Expert Opinion in Pharmacotherapy”
“Current Eye Research”

2011: invited reviewer for “Expert opinion in pharmacotherapy”
“Journal of ocular pharmacology and therapeutics”
“Current eye research”
“Achives of ophthalmology”

2012: invited review for “BMC ophthalmology”
“clinical ophthalmology”
“international journal of general practice”
“current medical literature-ophthalmology”

2013:invited review for “Scientific reports”
“British journal ophthalmology”
“international journal of ophthalmology”
“expert opinion on pharnacotherapy”
“Qure”
“clinical ophthalmology”

2014: invited reviewer for “Medicine”
“Evidence-Based Complementary and Alternative
Medicine”
“European Ophthalmic review”
“JOPT”
“cutaneous and ocular toxicology”
“open journal of ophthalmology”
“clinical and experimental ophthalmology”

“Journal of ophthalmology”
“Indian journal of ophthalmology”
“expert opinion on pharmacotherapy”

2015: invited reviewer for “Open Ophthalmology journal”
“Drugs and ageing”
“Ophthalmic Epidemiology”
“Ophthalmology and Ophthalmic Surgery”
“JOPT” (JOP-2015-0081)

2016: invited reviewer for
”Expert Review Ophthalmology” (ERL-2016-0013)
“PLOSone” (PONE-D-16-21557)
“JOPT” (JOP-2016-0133)
“Acta ophthalmologica”(ACTA-16-10-1197)
“Journal of Ophthalmology”
“JOPT” (JOP-2016-0077)
“Expert opinion on pharmacotherapy” (EOOP-2015-0372)

2017: invited reviewer for

“PLOS one” (PONE-D-17-03479)
“Ophthalmic epidemiology” (NOPE-2017-0038)
“Japanese journal of Ophthalmology”
“cutaneous and ocular toxicology”(LCOT-2017-0066)
”BMC Ophthalmology” (BOPH-D-17-00252)
“The Cochrane review” (Cochrane diagnostic test
accuracy review on occludable angles)
“Acta ophthalmologica" (ACTA-16-11-1362)
“Current eye research” (NCER-2017-0603)
“international Journal of Ophthalmology” (IJO-2017-
0957)

2018: invited reviewer for
“cornea “ (CORNEA-D-17-01129)
“Drug development and industrial Pharmacy" (LDDI-
2018-0007)
“ Expert opinion pharmacotherapy” (EOOP-2018-0117)
“ Expert review of ophthalmology”(ERL-2018-ST-0049
“ Asia-Pacific Journal of ophthalmology “(APJO2018323)

2019: invited reviewer for:
British Journal Ophthalmology (BJO 2019-314745)
Eye and Vision (EAVI-D-19-00275)
BMC Ophthalmology (BOPH-D-19-00252)

2020: invited reviewer for:
Cochrane
BJO (bjophthalmol-2019-315745.R1)
J of Ophthalmol
BMJ Open (bmjopen-2020-039209)
BMJ Open (bmjopen-2020-045275)

2021: invited reviewer for:
CMRO 2020-FT-0933
BMC Ophthalmology (ID 1b644009-d1bf-459c-bfa3-5574d4856c24)
Clinical Ophthalmology [ID: 310665]
Scientific Reports ID da52c2fb-861d-4028-ac69-66ce98829aeb
Journal of clinical Medicine (jcm-1216668)
International J of molecular sciences (ijms-1297953)
Eye and Vision (EAVI-D-21-00416)
Acta Ophthalmologica (ACTA-21-05-0822.R1)
J of ophthalmology (ID 3478470)
Frontiers in Aging Neuroscience (ID 744139)
J clinical medicine (ID: jcm-148289)
Pharmaceuticals (ID: 1539739)

2022: invited reviewer for:
pharmaceuticals-1539739
JOPT: JOP-2021-0122.R1
international J mol Sciences : ijms-1601396

	<p>Editing activity</p> <ul style="list-style-type: none"> -Member of Editorial board of International Journal of molecular sciences -Member of Editorial Board of Frontiers in neurology -Guest leading editor: for Journal of Ophthalmology (2018-2019) -Guest Associate Editor for the journal Frontiers in Neurology with the Topic research: Neuroinflammation and the visual system (call opened on April 2020) -Guest Associate Editor for the journal Frontiers in Ageing neurosciences with the Topic research: Glaucoma and Brain: Impact of Neurodegeneration on Visual Abilities and Related Biomarkers. (Call opened on February 2021) -Guest editor Healthcare: Healthcare and Diseases Control Measures in Ophthalmology <p>Member of the reviewer board</p> <ul style="list-style-type: none"> -International Journal of Molecular Sciences <p>Since 2022, Consultant of the Ethics Committee Vasta Emilia Centro Area (hereinafter CE-AVEC), IRCCS University Hospital of Bologna, S. Orsola-Malpighi Hospital, for clinical studies on ophthalmology.</p>
<i>Computer skills and competences</i>	<p>Excellent knowledge of software Microsoft Word, PowerPoint, Excel, Access, Publisher, and their application</p> <p>Excellent knowledge and use of Internet</p>
Artistic skills and competences	Painting and playing piano
Other skills and competences	<p>Awards</p> <ul style="list-style-type: none"> - Premio di Studio Armando Merli, Unione Italiana Ciechi sez Pavia, Dicembre 1997 - Premio di Studio Armando Merli, Unione Italiana Ciechi sez Pavia, Dicembre 1998 - MSD International award 2000; finalist with the paper: “Glaucomatous therapy’s impact on quality of life. Personal experience”, giugno 2000, Londra - MSD International award 2006 winner with the paper “Visual field (VF), GDx and HRT in the follow-up of glaucoma patients with well (<15 mmHg) or not well (>15 mmHg) controlled IOP” feb 2006, San Paolo, Brasil - Best paper EGS

Driving licence	European, B
Additional information	<p data-bbox="493 268 667 302"><i>Publications:</i></p> <ol data-bbox="493 352 1497 1925" style="list-style-type: none"> <li data-bbox="493 352 1497 457">1. Ruberto G, Rossi GCM, Gelmi C et al: Relazione tra Retinopatia Pigmentosa e Glaucoma ad angolo chiuso”, Annali di Ottalmologia e Clin Oculistica, vol. CXXI-10, 1995, Maccari. <li data-bbox="493 464 1497 569">2. Milano G, Rossi GCM, Guasconi A et al: Follou-up of patients at risk for glaucoma with Short Wavelength Automated Perimetry (SWAP), Vision Research, 1996, 36 (suppl), S152: 025. <li data-bbox="493 575 1497 716">3. Milano G, Rossi GCM, Veneziano F et al: Protective effect of topical beta-blockers in ocular hypertension: a study with Short Wavelength Automated Perimetry, Invest Ophthalmol & Vis Sci, 1997, 39; 2595-B285: S558. <li data-bbox="493 722 1497 863">4. Milano G, Guasconi A, Rossi GCM, et al: Light sensitivity in ocular hypertension treated by topical beta-blockers: a Study with White-on-White and Blue-on-Yellow Automated Perimetry, Ophthalmic Res, 1997, 091: 36. <li data-bbox="493 869 1497 974">5. Milano G, Rossi GCM, Ruberto G et al: Color vision and contrast sensitivity in early diagnosis of primary open angle glaucoma, Invest Ophthalmol & Vis Sci, 1998, 39: 2257-B114: S492. <li data-bbox="493 980 1497 1085">6. Rossi GCM, Milano G, Trimarchi F: Effect of topical on white-on-white and blue-on-yellow automated perimetry in ocular hypertensives, Exp Eye Res, 1998, 67 (suppl); 15-507: S153. <li data-bbox="493 1092 1497 1197">7. Rossi GCM, Milano G, Tinelli C et al: Visual functioning and quality of life in patients with glaucoma, Ophthalmic Res, 1999, 31 (suppl); 244: 43. <li data-bbox="493 1203 1497 1308">8. Rossi GCM, Milano G, Tinelli C et al: The 25-item National Eye Institute-Visual Functioning Questionnaire in patients with different eye diseases, Ophthalmic Res, 1999, 31 (suppl), 1323: 94. <li data-bbox="493 1314 1497 1419">9. Milano G, Rossi GCM, Trimarchi F: Automated Perimetry, Color Vision and Contrast Sensitivity in Ocular Hypertensives; in Perimetry update, The Hague, Kugler Publications, 1999, 317-321. <li data-bbox="493 1425 1497 1566">10. Rossi GCM, Milano G, Clemente A et al: The italian version of the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ 25 item): translation, validation, reliability, Invest Ophthalmol & Vis Sci, 2000, 39: 2498-B74. <li data-bbox="493 1572 1497 1677">11. Rossi GCM, Milano G, Tinelli C: The Italian version of the 25-item National Eye Institute Visual Function Questionnaire: Translation, Validity and Reliability, J Glaucoma, 2003, 12: 213-220. <li data-bbox="493 1684 1497 1747">12. Milano G, Rossi GCM, Clemente A, Pasinetti GM “Glaucoma’s impact on quality of life” Ophthalmic Res, 2003, 35 (suppl 1); <li data-bbox="493 1753 1497 1858">13. Milano G, Rossi GCM , Clemente A “SITA SWAP and FDT in early glaucoma patients, ocular hypertensives and normals” Ophthalmic Res, 2003, 35 (suppl 1); <li data-bbox="493 1864 1497 1925">14. Rossi GCM, Milano G , Tinelli C: “25-item National Eye Institute Visual Function Questionnaire (VFQ 25). Italian version.” In “Compendium of

quality of life instruments”, Cardiff, UK, 2004;

15. kernt K, Martinez M, Bertin D et al “a clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis”, *Eur J Ophthalmol* 2005;15:541-9
16. Topouzis F, Melamed S, Danesh-Meyer H, Wells AP, Kozobolis V, Wieland H, Andrew R, Wells D (Rossi G) A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension *Eur J ophthalmol* 2007;17:183-190.
17. Blini M, Rossi GCM, Trabucchi G, Curatola M, David A, Radaeli R, Merlo G, Ratiglia R: “Ocular hypotensive efficacy and safety of Travoprost 0.004% in inadequately controlled primary open angle glaucoma or ocular hypertension: short-term, multicenter, prospective study”, *Curr Med Res Opinion* 2009; 25: 57-63. DOI 10.1185/03007990802569315
18. Rossi GCM, Tinelli C, Pasinetti GM, Milano G, Bianchi PE: “Dry eye syndrome-related quality of life in glaucoma patients” *Eur J Ophthalmol* 2009; 4:572-79
19. Rossi GCM, Pasinetti GM, Bracchino M, Bucarelli M, Franchin S, Cerqueti P, Bellini R, Caravati C, et al: “Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study” *Expert Opin Pharmacother* 2009;10:1705-1711.
20. Rossi GCM, Lanteri S, Ricciardelli G, Raimondi M, Mogavero V, Bordin M, Milano G, Bianchi PE *Glaucoma e qualità di vita. Bollettino della Società medico chirurgica pavese* 2009, 122.
21. GCM Rossi, S Lanteri, M Raimondi, Bordin M, GM Pasinetti, M Bracchino, M Bucarelli, PE Bianchi, S Franchin, C Tinelli. Efficacia e sicurezza del passaggio dalla terapia di associazione non fissa Latanoprost 0.005% e Timololo 0.5% alla combinazione fissa Travoprost 0.004%/Timololo 0.5%. Studio di coorte, multicentrico su pazienti affetti da glaucoma o ipertono oculare. *Bollettino della Società medico chirurgica pavese* 2009, 122.
22. Rossi GCM, Raimondi M, Lanteri S, Bordin M, Milano G, Bianchi PE “Possiamo individuare i pazienti a rischio di scarsa aderenza alla terapia?” *Minerva Oftalmol* 2010; 52S:24.
23. Rossi GCM, Pasinetti GM, Scudeller L, Tinelli C, Bianchi PE: “Monitoring adherence rates in glaucoma patients using Travatan Dosing Aid. A six months study comparing patients on Travoprost 0.004% and patients on Travoprost 0.004%/Timolol 0.5% fixed combination”. *Expert Opin Pharmacother* 2010; 11(4):499-504.
24. Balestrazzi E, Spadea L, Martini E, Rossi PL, D’Andrea D, Marangolo L, Saviano BM, Colotto, Salgarello T, Macrì A, Saccà SC, Rossi GCM: Efficacia ipotonizzante e tollerabilità di Travoprost in pazienti con glaucoma primario ad angolo aperto e/o ipertensione oculare, non controllati dal trattamento con Dorzolamide+Timololo in associazione fissa, o intolleranti ad essa. *Ottica Fisipatologica* 2010,15:35-43.

25. Pianini V, Rossi GCM, Passani A, Passani F Efficacy and safety of Netilmycin/Dexamethasone preservative free and Tobramycin/Dexamethasone preserved fixed combination in patients after cataract surgery. *Journal Ocular Pharmacology and Ther* 2010; 26:617-21.
26. Rossi GCM, Pasinetti GM, Briola A, Bianchi PE. Effect of glaucoma medications on quality of life examined by generic and vision specific instruments. *Journal of Clinical and Experimental ophthalmology*, 2010; 1:106. doi 10.4172/2155 9570.1000106.
27. Rossi GCM, Signs and symptoms of ocular surface status in glaucoma patients switched from Timolol 0,5% to Brinzolamide 1%/Timolol 0,5% fixed combination. A 6 months, multicenter, open label and prospective study *Exp Opin Pharmacother* 2011;12:685-90. Epub 2011 Mar 9. (3.123)
28. Rossi GCM, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE Do adherence rates and glaucomatous visual field correlate? *Eur J Ophthalmol*. 2011;21:410-414. doi: 10.5301/EJO.2010.6112 (IF 1.272)
29. Rossi GC, Pasinetti GM, Bordin M, Sandolo F, Bianchi PE. From Dorzolamide 2%/Timolol 0,5% to Brinzolamide 1%/Timolol 0,5% fixed combination: a 6 months, tolerability, multicenter, open-label switch study *Exp Opin Pharmacother* 2011 Nov; 12(16): 2425-31. doi: 10.1517/14656566.2011.589384. Epub 2011 Jun 16. (IF 3.123)
30. Rossi GCM How to diagnose the ocular surface disease in treated glaucoma patients. *European Ophthalmic Review* 2011;5(1):38-42 doi:10.17925/EOR.2011.05.01.38.
31. Rossi GCM, Scudeller L, Delfino A, Raimondi M, Pezzotta S, Maccarone M, Antoniazzi E, Pasinetti GM, Bianchi PE Pentacam's sensitivity and specificity in detecting occludable angles. *Eur J Ophthalmol* 2012;22(5):701-8. doi: 10.5301/ejo.5000108 (IF 1.290)
32. Rossi GCM, . Efficacy and ocular surface tolerability of preservative free tafluprost 0.0015%: a 6 months, single blind, observational study on naïve ocular hypertension or glaucoma patients. *Expert Opin Drug Safety* 2012; 11:519-525. (3.156)
33. Iester M, Telani S, Frezzotti P, Manni GL, Uva M, Figus M, Perdicchi A; Italian Glaucoma Register. Differences in central corneal thickness between the paired eyes and the severity of the glaucomatous damage. *Eye* 2012;26:1424-3 DOI 010.1038/eye.2012.179 (2.401)
34. Rossi GCM, Pasinetti GM, Scudeller L, milano G, Mazzone A, Raimondi M, Bordin M, Lanteri S, Bianchi PE The Italian version of the Glaucoma Symptoms Scale: translation, validation and reliability. *J Glaucoma*. 2013 ;22:44-51 (IF 2.364)
35. Rossi G, Pasinetti GM, Scudeller L, Raimondi M, Lanteri S, Bianchi PE. Risk factors to develop ocular surface disease in treated glaucoma or hypertension patients. *Eur J Ophthalmol*. 2013 May-Jun;23(3):296-302. doi: 10.5301/ejo.5000220. Epub 2012 Dec 17 (1.450)
36. Rossi G, Pasinetti GM, Scudeller L, Bianchi PE. Ocular surface disease and glaucoma: how to evaluate impact on quality of life. *J Ocul Pharmacol Ther*. 2013 May;29(4):390-4. doi: 10.1089/jop.2011.0159.

Epub 2012 Dec 7. (2.009)

37. Iester M, Telani S, Brusini P, Rolle T, Fogagnolo P, Martini E, Milano G, Paoli D, Italian Glaucoma Register. Central corneal thickness and glaucoma treatment: an italian multicenter cross-sectional study. *J Ocul Phatmacol Ther* 2013 jun 29:469-73 DOI 10.1089/jop.2012.0116 (2.009)
38. Rossi GC, Blini M, Scudeller L Ricciardelli G, De Polo L, Amisano A, Bossolesi L, Pasinetti GM, Bianchi PE Effect of preservative-free Tafluprost on keratocytes, sub-basal nerves, and endohelium: a single blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group. *J Ocul Pharmacol Ther* 2013; 29:821-25. (IF 2.009)
39. Rossi Gemma CM Diagnosis and treatment methods for ocular surface disease in glaucoma. *European Ophthalmic Review* 2014; 8(1):40-3 DOI: <http://doi.org/10.17925/EOR.2014.08.01.40>:
40. Rossi GC, Scudeller L, Rolle T, Pasinetti GM, Bianchi PE. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability. *Expert Opinion Drug Safety* 2015; 10:1-5. (IF 3.471)
41. Pezzotta S, Rossi GC, Scudeller L, Antoniazzi E, Bianchi PE, Perotti C, Del Fante C. A cross-sectional study on vision-related quality of life in patients with ocular GvHD. *Bone Marrow Transplant.* 2015 Sep;50(9):1224-6. doi: 10.1038/bmt.2015.24. Epub 2015 Jun 8. (IF 3.943)
42. Floriani I, Quaranta L, Rulli E, Katsanos A, Varano L, Frezzotti P, Rossi GC, Carmassi L, Rolle T, Ratiglia R, Gandolfi S, Fossarello M, Uva M, Hollander L, Poli D, Grignolo F; Italian Study Group on QoL in glaucoma. Health-related quality of life in patients with primary open-angle glaucoma. An Italian multicentre observational study. *Acta Ophthalmol.* 2016 Aug;94(5):e278-e286. doi: 10.1111/aos.12890. Epub 2015 Nov 19 (IF 3.157)
43. Pezzotta S, Del Fante C, Scudeller L, Rossi GC, Perotti C, Bianchi PE, Antoniazzi E. Long-term safety and efficacy of autologous platelet lysate drops for treatment of ocular GvHD. *Bone Marrow Transplant.* 2017 Jan;52(1):101-106. doi: 10.1038/bmt.2016.221. Epub 2016 Sep 5 (IF 4.704)
44. JGFeijoo, FJ Munoz-Negrete, DA Hubatsch, GC Rossi. Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. *Clin Ophthalmol.* 2016 Oct 21;10:2085-2091. eCollection 2016. (IF 1.91)
45. Christophe Baudouin, David J. Galarreta, Ewa Mrukwa-Kominek, Daniel Böhringer, Vincenzo Maurino, Michel Guillon, Gemma Caterina Maria Rossi, Ivanka J. Van der Meulen, Abayomi Ogundele, Marc Labetoulle. Clinical Evaluation of an Oil-based Lubricant Eye Drop in Dry Eye Patients With Lipid Deficiency. *Eur J Ophthalmol.* 2017 Mar 10;27(2):122-128. doi: 10.5301/ejo.5000883. Epub 2016 Oct 27. (IF 1.578)
46. Rulli E, Quaranta L, Riva I, Poli D, Hollander L, Galli F, Katsanos A,

- Oddone F, Torri V, Weinreb RN; Italian Study Group on QoL in Glaucoma. Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study. *Sci Rep.* 2018 Jan 12;8(1):619. doi: 10.1038/s41598-017-19113-z. (IF 4.576)
47. Riva I, Legramandi L, Katsanos A, Oddone F, Rulli E, Roberti G, Quaranta L; Italian Study Group on QoL in Glaucoma. Influence of Sociodemographic Factors on Disease Characteristics and Vision-related Quality of Life in Primary Open-angle Glaucoma Patients: The Italian Primary Open Angle Glaucoma Study (IPOAGS). *J Glaucoma.* 2018 Sep;27(9):776-784. doi: 10.1097/IJG.0000000000000989. (IF 1.992)
48. Riva I, Legramandi L, Rulli E, Konstas AG, Katsanos A, Oddone F, Weinreb RN, Quaranta L; Italian Study Group on QoL in Glaucoma. Vision-related quality of life and symptom perception change over time in newly-diagnosed primary open angle glaucoma patients. *Sci Rep.* 2019 May 1;9(1):6735. doi: 10.1038/s41598-019-43203-9. (IF 4.576)
49. Rossi Gemma CM. Age and gender influence reaction to glaucoma diagnosis. *European Ophthalmic review* 2018;12:85-87.
50. Rossi GCM, Scudeller L, Lumini C, Mirabile AV, Picasso E, Bettio F, Pasinetti GM, Bianchi PE. An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. *Sci Rep.* 2019 Mar 12;9(1):4282. doi: 10.1038/s41598-019-41038-y. (IF 4.576)
51. Rossi GCM, Scudeller L, Bettio F, Pasinetti GM, Bianchi PE. Prevalence of dry eye in video display terminal users: a cross-sectional Caucasian study in Italy. *Int Ophthalmol.* 2019 Jun;39(6):1315-1322. doi: 10.1007/s10792-018-0947-6. Epub 2018 Jun 7. (IF 1.314)
52. Quaranta L, Riva I, Biagioli E, Rulli E, Rulli E, Poli D, Legramandi L; CoQun® Study Group. Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol. *Advances in Therapy.* 2019 Sep;36(9):2506-2514. doi: 10.1007/s12325-019-01023-3. Epub 2019 Jul 12. (IF 3.871)
53. Rossi GCM Dry eye in video display terminal users. Expert interview. *European Ophthalmic review* 2019;13(2):67-68. doi.org /10.17925/EOR.2019.13.2.67.
54. Oddone F, Tanga L, Kóthy P, Holló G; VISIONARY Study Group. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study. *Adv Ther.* 2020 Apr;37(4):1436-1451. doi: 10.1007/s12325-020-01239-8. (IF 3.845)
55. Rossi GCM, Scudeller L, Lumini C, Bettio F, Picasso E, Ruberto G, Briola A, Mirabile A, Paviglianiti A, Pasinetti GM, Bianchi PE. Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram. *Sci Rep.* 2020 Jun 26;10(1):10468. doi: 10.1038/s41598-020-67527-z. (IF 4.576)
56. Marino PF, Rossi GCM, Campagna G, Capobianco D, Costagliola C and on behalf of QUALICOS Study Group. Effects of Citicoline, Homotaurine, and Vitamin E on Contrast Sensitivity and Visual-Related

Quality of Life in Patients with Primary Open-Angle Glaucoma: A Preliminary Study. *Molecules* 2020, 25, 5614; doi:10.3390/molecules25235614. (IF 3.267)

57. LM Nijm, L De Benito-Llopis, GC Rossi, TS Vajaranant, MT Coroneo. Understanding the Dual Dilemma of Dry Eye and Glaucoma: An International Review. *Asia Pac J Ophthalmol (Phila)* 2020;9:481–490 . DOI 10.1097/APO.0000000000000327 (IF 2.25)
58. Rossi Gemma C, Gandini Weeler-Kingshot C, Toosy A. Editorial: Neuroinflammation and the visual system, *Front Neurol* 2021;12:724447. DOI 10.3389/fneur.2021.724447. (IF 4.003)
59. Rossi GCM, Scudeller L, Bettio F, Milano G.A Pilot, Phase II, Observational, Case-Control, 1-Month Study on Asthenopia in Video Terminal Operators without Dry Eye: Contrast Sensitivity and Quality of Life before and after the Oral Consumption of a Fixed Combination of Zinc, L-Carnitine, Extract of Elderberry, Currant and Extract of Eleutherococcus. *Nutrients* 2021;13,4449. [https://doi.org/ 10.3390/nu13124449](https://doi.org/10.3390/nu13124449) (IF 5.429)
60. Rossi GCM, Bettio F, Gonzalez-Perez M, Briola A, Pasinetti GL, Scudeller L. The 17-item Computer Vision Symptom Scale questionnaire (CVSS17). *International Journal of Environmental Research and Public Health* 2022 doi.org/10.3390/(IF 3.390). IN PRESS

Feb, 21 2022	